Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.75 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | ADH1B | P00325 | 2/20 | 0.41 |
| ▸ | ADH1A | P07327 | 2/20 | 0.41 |
| ▸ | ADH7 | P40394 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butanal SCHEMBL3515924 | 1.00 | ALDH1A1 (0.75) | ALDH1A1TSHRADH1BADH1AADH7 | |
| Butanal SCHEMBL2182916 | 1.00 | — | — | |
| Butanal SCHEMBL7746906 | 0.94 | — | — | |
| Butanal SCHEMBL11736874 | 0.90 | — | — | |
| Butanal SCHEMBL10448612 | 0.87 | — | — | |
| Butanal SCHEMBL7323870 | 0.87 | — | — | |
| Butanal SCHEMBL597713 | 0.87 | ALDH1A1 (1.00) | ALDH1A1TSHRADH1BADH1AADH7 | |
| Butanal SCHEMBL9303364 | 0.87 | ALDH1A1 (1.00) | ALDH1A1TSHRADH1BADH1AADH7 | |
| Butanal SCHEMBL807 | 0.87 | — | — | |
| Butanal SCHEMBL6441925 | 0.86 | ALDH1A1 (0.63) | ALDH1A1TSHRADH1BADH1AADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113413-A1 | POLYMER DERIVATIVES HAVING PARTICULAR ATOM ARRANGEMENTS | NEKTAR THERAPEUTICS (US) | 2023-04-13 | — | — | US | disclosed |
| EP-2214716-B1 | HYDROXYAPATITE-TARGETING MULTIARM POLYMERS AND CONJUGATES MADE THEREFROM | NEKTAR THERAPEUTICS (US) | 2021-11-17 | — | — | EP | disclosed |
| EP-1546235-B1 | WATER-SOLUBLE POLYMER ALKANALS | NEKTAR THERAPEUTICS (US) | 2021-10-20 | — | — | EP | disclosed |
| US-20200246471-A1 | POLYMER DERIVATIVES HAVING PARTICULAR ATOM ARRANGEMENTS | NEKTAR THERAPEUTICS (US) | 2020-08-06 | — | — | US | disclosed |
| US-10646578-B2 | Polymer derivatives having particular atom arrangements | NEKTAR THERAPEUTICS (US) | 2020-05-12 | — | — | US | disclosed |
| EP-2644206-B1 | PEG derivatives containing two PEG chains | NEKTAR THERAPEUTICS (US) | 2019-04-03 | — | — | EP | disclosed |
| US-20190022236-A1 | POLYMER DERIVATIVES HAVING PARTICULAR ATOM ARRANGEMENTS | NEKTAR THERAPEUTICS | 2019-01-24 | — | — | US | disclosed |
| US-9913913-B2 | Method for preparing a polymeric reagent | NEKTAR THERAPEUTICS (US) | 2018-03-13 | — | — | US | disclosed |
| US-20160324974-A1 | METHOD FOR PREPARING A POLYMERIC REAGENT | NEKTAR THERAPEUTICS | 2016-11-10 | — | — | US | disclosed |
| US-9399070-B2 | Compositions comprising a polymeric reagent and a pharmacologically active agent | NEKTAR THERAPEUTICS (US) | 2016-07-26 | — | — | US | disclosed |
| US-7157546-B2 | Polyoxyethylene glycol; purity, storage stability | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060275252-A1 | Conjugates formed from polymer derivatives having particular atom arrangements | NEKTAR THERAPEUTICS | 2006-12-07 | — | — | US | disclosed |
| US-20060194940-A1 | 2-methylbutyraldehyde diethyl acetal end capped polyoxyethylene glycol; polyalkylene oxide, polyivnylpyrrolidone, polyvinyl alcohol, polyoxazoline etc. endcapped with polyetherpolyamine copolymers or oligomers covalently attached to diacetal tetramethylene group | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2006-08-31 | — | — | US | disclosed |
| EP-1626741-A2 | PEG DERIVATIVES HAVING AN AMIDOCARBONATE LINKAGE | Nektar Therapeutics Al, Corporation (US) | 2006-02-22 | — | — | EP | disclosed |
| EP-1591467-A1 | Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone | Nektar Therapeutics Al, Corporation (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1546235-A2 | WATER-SOLUBLE POLYMER ALKANALS | Nektar Therapeutics Al, Corporation (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050009988-A1 | Polymer derivatives having particular atom arrangements | NEKTAR THERAPEUTICS | 2005-01-13 | — | — | US | disclosed |
| WO-2005000360-A2 | PEG DERIVATIVES HAVING AN AMIDOCARBONATE LINKAGE | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040116649-A1 | Polyoxyethylene glycol; purity, storage stability | NEKTAR THERAPEUTICS | 2004-06-17 | — | — | US | disclosed |
| WO-2004022630-A2 | WATER-SOLUBLE POLYMER ALKANALS | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009988-A1 | Polymer derivatives having particular atom arrangements | CD44, PIGO, PGLS | ALDH1A1 1192/4885TSHR 4119/4885ADH1B 1261/4885 |
| US-20190022236-A1 | POLYMER DERIVATIVES HAVING PARTICULAR ATOM ARRANGEMENTS | CD44, PIGO, PGLS | ALDH1A1 1192/4885TSHR 4119/4885ADH1B 1261/4885 |
| US-20230113413-A1 | POLYMER DERIVATIVES HAVING PARTICULAR ATOM ARRANGEMENTS | CD44, PIGO, PGLS | ALDH1A1 1192/4885TSHR 4119/4885ADH1B 1261/4885 |
| US-10646578-B2 | Polymer derivatives having particular atom arrangements | CD44, PIGO, PGLS | ALDH1A1 1192/4885TSHR 4119/4885ADH1B 1261/4885 |
| US-20160324974-A1 | METHOD FOR PREPARING A POLYMERIC REAGENT | SI, PAICS, DNPEP | ALDH1A1 433/4885TSHR 1755/4885ADH1B 584/4885 |
| US-20200246471-A1 | POLYMER DERIVATIVES HAVING PARTICULAR ATOM ARRANGEMENTS | CD44, PIGO, PGLS | ALDH1A1 1192/4885TSHR 4119/4885ADH1B 1261/4885 |
| US-20060275252-A1 | Conjugates formed from polymer derivatives having particular atom arrangements | CD44, PAICS, PIGO | ALDH1A1 1078/4885TSHR 3699/4885ADH1B 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.